Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Breast 1

Conditions

Pancreatic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × andecaliximab × Breast × Clear all
NCT01803282 2020-06-02

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Gilead Sciences

Phase 1 Completed
236 enrolled 21 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡